...
首页> 外文期刊>Bioorganic and Medicinal Chemistry Letters >Design, synthesis and evaluation of pyrrolo[2,3-d]pyrimidine-phenylamide hybrids as potent Janus kinase 2 inhibitors
【24h】

Design, synthesis and evaluation of pyrrolo[2,3-d]pyrimidine-phenylamide hybrids as potent Janus kinase 2 inhibitors

机译:设计,合成和评价吡咯并[2,3-d]嘧啶-苯酰胺杂化物作为有效的Janus激酶2抑制剂

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Janus kinase 2 (JAK2) plays an essential role in the signaling of hormone-like cytokines and growth factors, which has been convinced as an important target of myeloproliferative neoplasms (MPNs) therapy. In this study, a series of novel pyrrolo[2,3-d] pyrimidine-phenylamide hybrids were designed and synthesized as potential JAK2 inhibitors through hybridization strategy. In vitro biological studies showed that most of these compounds exhibited potent activity against JAK2. Especially, compound 16c was identified as a suitable lead compound, which showed favorable pharmacokinetic profiles in rats (F = 73.57%), excellent in vitro efficacy against erythroleukemic cells (TF-1, IC50 = 0.14 mu M), and high selectivity for JAK2 (IC50 = 6 nM with > 97-fold selectivity vs JAK3). (C) 2016 Elsevier Ltd. All rights reserved.
机译:Janus激酶2(JAK2)在激素样细胞因子和生长因子的信号传导中起着至关重要的作用,已被认为是骨髓增生性肿瘤(MPNs)治疗的重要靶标。在这项研究中,设计了一系列新颖的吡咯并[2,3-d]嘧啶-苯酰胺杂化物,并通过杂交策略合成为潜在的JAK2抑制剂。体外生物学研究表明,这些化合物大多数都表现出对JAK2的有效活性。尤其是,化合物16c被确定为合适的先导化合物,在大鼠中表现出良好的药代动力学特征(F = 73.57%),在体外对红白血病细胞具有优异的疗效(TF-1,IC50 = 0.14μM),并且对JAK2具有高选择性(IC50 = 6 nM,相对于JAK3具有> 97倍的选择性)。 (C)2016 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号